ABSTRACT
Cardiovascular complications of chemotherapy: A synopsis
progressive; and late-onset chronic progressive. (1, 2) Acute cardiotoxicity is rare. It occurs immediately after infusion of the anthracycline and manifests as a transient acute decline in LV function which is usually reversible.
The early-onset chronic progressive form occurs in patients during therapy or within the first year of therapy.
Late-onset chronic progressive anthracycline-induced cardiotoxicity occurs at least 1 year after completion of therapy. Early and late-onset chronic progressive cardiotoxicity typically presents as a CMO in adults which can progress to heart failure. (2) Cardiotoxicity may only become clinically evident 10 to 20 years after the first dose of chemotherapy.
The risk of cardiotoxicity increases with cumulative doses of anthracyclines. The cumulative dose of doxorubicin above which cardiotoxicity occurs is >400mg/m2. (3, 4, 5) For this reason the maximum lifetime cumulative dose of doxorubicin is 400 to 550mg/m2.
Epirubicin or idarubicin appear to have less incidence of HF. (6, 7) Apart from the cumulative dose, the risk factors for anthracycline toxicity include: intravenous bolus administration; higher single doses; history of prior irradiation; the concomitant use of other agents such as cyclophosphamide; trastuzumab and paclitaxel (known to have cardiotoxic effects); female gender; pre-existing cardiovascular disease; age (both young and old); and increased length of time since anthracycline completion. (1, 2) Morningside Medi Clinic, Sandton, South Africa
INTRODUCTION
Cancer treatment frequently entails the combined use of chemotherapy, radiotherapy and surgery to prolong life and provide a cure. Both chemotherapy and radiotherapy have the potential to cause acute or long term cardiovascular complications. The cardiovascular complications of chemotherapy include heart failure, myocardial ischaemia or infarction, thromboembolism, hypertension and arrhythmias. This article reviews the incidence and effects of the various forms of cardiotoxicity caused by both the older and more recent chemotherapeutic agents currently used to treat cancer.
LEFT VENTRICULAR (LV) DYSFUNCTION
Many chemotherapeutic agents have been linked to the development of left ventricular dysfunction (LVD) ( Table 1 ) and/or heart failure (HF). The cumulative dose, administration schedule and concomitant use of other cardiotoxic therapies determine the likelihood of cardiomyopathy (CMO).
Anthracyclines
The anthracycline class of agents is commonly used in the management of a variety of malignancies, most frequently as adjuvant therapy for breast cancer and as systemic treatment of sarcomas, lymphomas and leukaemias. Formal estimates of the worldwide prevalence of anthracycline cardiotoxicity are lacking.
Differences among paediatric, adult and elderly populations and the lack of universal criteria for detecting and reporting cardiac events make such estimates even more challenging. Anthracycline cardiotoxicity has been classified into acute; early-onset; chronic; Alkylating agents Cyclophosphamide (14) Ifosfamide (15) Anti-metabolites
Proteosome inhibitor Bortezomib (16) Antibody-based tyrosine kinase inhibitors Bevacizumab (8) Trastuzumab (9) (10) (11) Small molecule tyrosine kinase inhibitors Dasatinib (17) Lapatinib (18) Imatinib (17) Sunitinib (19) Her2-positive breast cancer) and HERA (13) (a multicentre randomised trial comparing 1 or 2 years of trastuzumab treatment after standard chemotherapy), have reported the lowest rates of significant cardiac dysfunction. In contrast to anthracycline-medicated toxicity, which tends to be dose dependent and irreversible, trastuzumab-related cardiotoxicity generally is not dose dependent nor associated with structural changes on biopsy and tends to be reversible. The majority of patients recover though typically continue using cardiac medications.
Alkylating agents
Cardiotoxicity has been associated with cyclophosphamide therapy. (14) Patients may present with pericardial effusions, HF or myopericarditis. The risk of cardiotoxicity appears to be dose related (>150mg/kg and 1.5g/m2/day) and occurs within 1 to 10 days after the administration of the first dose. Other risk factors include prior anthracycline or mitoxantrone therapy and mediastinal radiation. (6) Another alkylating agent ifosfamide may also be responsible for cardiotoxicity when used in combination with other agents. (9) Acute onset of HF occurred within 6 to 23 days after the first dose and a dose response trend was observed (doses >12.5g/m2). (15) Other agents
A host of other chemotherapeutic agents can cause LVD including anti-metabolites such as clofaribine which may cause transient LVD in paediatric patients treated for acute lymphoblastic leukaemia. The proteasome inhibitor bortezomib used in the treatment of multiple myeloma can also cause LVD.
The small molecule tyrosine kinase inhibitors such as dasatinib (17) used in the treatment of leukaemia, lapatinib (18) approved for the treatment of trastuzumab-resistant breast cancer and sunitinib (19) used in stromal tumours and renal carcinoma have all been implicated in causing LVD. CMO related to sunitinib may not be reversible.
Diagnosis of Left Ventricular Dysfunction (LVD) and Heart Failure (HF)
The diagnosis of HF is established by combining the clinical history, examination, electrocardiogram, chest radiography, laboratory tests and non-invasive imaging. (20) Biochemical markers such as troponin I (21) and B-type natriuretic peptide (22) may detect myocardial injury before changes in LVEF become apparent.
Echocardiography with speckle tracking could be the most sensitive method of detecting early cardiac dysfunction. 
Prevention of LVD and HF
The most significant factor for anthracycline-induced CMO is the cumulative dose the patient has received and therefore prevention necessitates minimizing the patient's lifetime cumulative dose.
Other preventive measures include altering the method of administration (continuous vs. bolus), use of anthracycline analogues and the addition of cardioprotectants such as dexrazoxane. 
To date 4 case series have evaluated the use of beta blockers in treatment of anthracycline-induced CMO and found to be beneficial. (26) Carvedilol may have an advantage because of its antioxidant properties. (27) The classification of cardiotoxicity varies and is based on clinical radionuclide angiography and/or echocardiographic criteria. It can be classified as mild (a decrease in EF >10% from baseline with a final value of >50%); moderate (a decrease in EF of >10% from
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Volume 9 • Number 4 baseline with a final value of <50% and no symptoms or signs of heart failure); and severe (a decrease in EF of >10% from baseline with a final value of <50% and symptoms or signs of heart failure or a decrease in EF of any % leading to a final value of <40% irrespective of signs or symptoms of heart failure). (28, 29) 
MYOCARDIAL ISCHAEMIA
Although cardiac ischaemia is uncommonly related to chemotherapy an increased risk of acute coronary syndromes has been associated with cytotoxic agents. Chest pain is common in cancer patients often necessitating a work-up to exclude myocardial ischaemia.
Both radiotherapy and chemotherapy are associated with an increased risk of coronary artery disease and/or acute coronary syndromes (ACS). (30) Fluorouracil (5-FU) an anti-metabolite is one of the best known chemotherapeutic agents causing angina. In rare cases myocardial infarction (MI), arrhythmias, HF, cardiogenic shock and sudden death have been reported. (30) (31) Other chemotherapeutic agents including paclitaxel (32) and docetaxel (33) both anti-microtubular agents have also been associated with causing myocardial ischaemia and even infarction.
Chemotherapy agents implicated in the development of myocardial ischaemia/infarction are shown in Table 2 .
Treatment
Patients with ACS should be managed according to the usual guidelines. This may pose a problem in cancer patients because of thrombocytopaenia or recent surgery. In a retrospective study in patients with thrombocytopaenia, aspirin improved the outcome without increasing the risk of bleeding. (34) 
HYPERTENSION (HTN)
Hypertension and cancer are often found in the same patient.
Epidemiological studies suggest that there is an association between the two and that HTN affects the overall prognosis of cancer patients. More recent chemotherapeutic agents such as the VEGF inhibitors disrupt angiogenesis thus making these patients susceptible to developing HTN. 
Other agents inducing HTN include sorafenib (36) and sunitinib.
(37) Table 3 shows the incidence of HTN associated with some anticancer drugs.
Treatment of HTN
Standard anti-hypertensive therapy is indicated. Discontinuation of anti-angiogenic therapy causing HTN is controversial since the appearance of HTN seems to associate with a greater treatment response. (38) It may be beneficial to use ACE inhibitors as first line therapy due to their ability to prevent plasminogen activator inhibitor-1 expression. (39) Non-dihydropiridine calcium channel blockers such as diltiazem and verapamil should not be used in sorafenib-treated patients since they are both inhibitors of the CYP3A4 iso-enzyme. (40) (30) (31) Paclitaxel (32) Docetaxel (33) Bevacizumab ( and administration of concurrent chemotherapy. (41, 42, 43) Some drugs that have been associated with a greater risk of thrombo-embolism include cisplatin (44) used in renal tract carcinomas, vorinostat (45) used in T-cell lymphoma and thalidomide (41, 42) used for patients with myeloma. Table 4 shows the incidence of venous thromboembolism with selected agents.
BRADYCARDIA
A variety of circumstances may contribute to the development of bradycardia and heart block in cancer patients. The conduction system can be affected by fibrosis due to ageing, radiation therapy, amyloidosis or a primary cardiac tumour. Several chemotherapeutic agents most commonly paclitaxel and thalidomide may also cause heart block.
(46) Table 5 shows the incidence of heart block with selected agents.
QT PROLONGATION
The complications of QT interval prolongation including Torsade de Pointes are rare but can have life threatening consequences. Cancer patients may be particularly prone to QT prolongation since 16% to 36% of cancer patients have baseline ECG abnormalities. (47, 48) Cancer patients may have co-morbid diseases including structural heart disease, renal or hepatic dysfunction, as well as using other medications that may themselves prolong the QT interval. Cancer patients may develop electrolyte abnormalities because of nausea, vomiting, diarrhoea and decreased oral intake further predisposing to QT prolongation. (47, 48) The incidence of QT prolongation with the use of Arsenic Trioxide ranges widely in the published literature from 25%-90%. (49) The QT prolongation potential of both of dasatinib (50) and lapatinib (51) has been reported. Table 6 shows the incidence of QT prolongation associated with some cancer drugs.
CONCLUSION
Chemotherapy is associated with a wide variety of adverse cardiovascular effects. Patients need to be carefully monitored during and after their cancer treatment. Many cancer patients are not receiving treatment consistent with heart failure guidelines. (52) A great opportunity exists for closer collaboration between cardiologists and oncologists to improve the care of cancer patients receiving cardiotoxic therapy.
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